Adverse effects of ingredients available in single nasal decongestant formulation at trachea and lungs on an experimental rat model

Basit Öğe Kaydı
dc.authoridAkyüz Ünsal, Ayşe İpek / 0000-0001-5260-674X
dc.authoridDemirci, Buket / 0000-0002-3442-5061
dc.authorwosidAkyüz Ünsal, Ayşe İpek / A-4954-2016
dc.authorwosidDemir, Emre / AAA-8193-2020
dc.authorwosidDemirci, Buket / C-1006-2018
dc.contributor.authorArslan, Sertaç
dc.contributor.authorGüney, Güven
dc.contributor.authorAkyüz Ünsal, Ayşe İpek
dc.contributor.authorDemir, Emre
dc.contributor.authorDemirci, Buket
dc.date.accessioned2021-11-01T15:02:55Z
dc.date.available2021-11-01T15:02:55Z
dc.date.issued2019
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractBackground and Aim: There is little histologic data concerning effects of nasal decongestants on respiratory tract. We aimed to put forth the effects of mostly used ingredients of nasal decongestants on trachea and lower airways of rats. Materials and Method: Four-six months old 60 male rats were randomly categorized into 6 groups. Experimental drugs were applied to the same nostril twice daily for 8 weeks (Xylometazoline, Benzalkolyum, EDTA, Sorbitol and combined drug solution). Normal saline solution (NaCl % 0.9) applied for the controls. At the end, trachea and both lungs were dissected and kept in formaldehyde for histopathologic evaluation. Results: Inflammation and bronchial edema were most common findings. All rats in sorbitol group had increased numbers of type 2 pneumocytes. Eighty percent of BAC group had increased numbers of type 2 pneumocytes. Spillover of tracheal epithelium was seen mostly in sorbitol, EDTA and combined drug groups (60%, 87.5%, 50% respectively). Bronchial smooth muscle hypertrophy was seen mostly in BAC and EDTA group (70%, 62.5% respectively). Number of goblet cells showed significant difference between control-combined drug (p=0.025) and control-BAC (p=0.001) groups. Conclusion: Nasal decongestants might have adverse effects such as increased airway inflammation, edema, type 2 pneumocyte numbers and epithelial desquamation mostly.
dc.identifier.citationArslan, S., Güney, G., Ünsal, A. I. A., Demir, E., & Demirci, B. (2019). Adverse effects of ingredients available in single nasal decongestant formulation at trachea and lungs on an experimental rat model. MEDICAL SCIENCE, 23(95), 138-145.
dc.identifier.endpage145en_US
dc.identifier.issn2321-7359
dc.identifier.issn2321-7367
dc.identifier.issue95en_US
dc.identifier.startpage138en_US
dc.identifier.urihttps://hdl.handle.net/11491/6850
dc.identifier.volume23en_US
dc.identifier.wosWOS:000455062500024
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.institutionauthorDemir, Emre
dc.institutionauthorArslan, Sertaç
dc.institutionauthorGüney, Güven
dc.language.isoen
dc.publisherDiscovery Publication
dc.relation.ispartofMedical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subject[No Keywords]en_US
dc.titleAdverse effects of ingredients available in single nasal decongestant formulation at trachea and lungs on an experimental rat model
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu